Literature DB >> 15816519

A rapid HPLC method for the measurement of ultra-low plasma methionine concentrations applicable to methionine depletion therapy.

Xinghua Sun1, Yuying Tan, Zhijian Yang, Shukuan Li, Robert M Hoffman.   

Abstract

A rapid, sensitive and specific high-performance liquid chromatographic (HPLC) method for the separation and quantification of L-methionine in plasma has been developed. After derivatization of plasma amino acids with o-phthalaldehyde (OPA), a 50 microl sample was loaded on a reversed-phase Supelcosil LC-18-DB column (particle size 5 microm, 25 cm x 4.6 mm, 120A pores). A customized gradient program using tetrahydrofuran/methanol/0.1 M sodium acetate, pH 7.0, v/v/v=5/95/900 and methanol was used with detection by fluorescence. The elution time was 15 minutes, a 3-fold improvement over existing methods. The linearity was 1-100 microM. The limit of detection was 0.5 micromol/L, a 10-fold improvement over existing methods. The inter-assay CVs were 2-5%, and the intra-assays CVs were 4-8%. The sensitivity and rapidity of this HPLC method is particularly applicable to determine the efficacy of methionine depletion therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816519

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.

Authors:  Kei Kawaguchi; Kentaro Miyake; Qinghong Han; Shukuan Li; Yuying Tan; Kentaro Igarashi; Thinzar M Lwin; Takashi Higuchi; Tasuku Kiyuna; Masuyo Miyake; Hiromichi Oshiro; Michael Bouvet; Michiaki Unno; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-05-21       Impact factor: 4.534

2.  Methionine depletion with recombinant methioninase: in vitro and in vivo efficacy against neuroblastoma and its synergism with chemotherapeutic drugs.

Authors:  Jian Hu; Nai-Kong V Cheung
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

3.  Linkage of methionine addiction, histone lysine hypermethylation, and malignancy.

Authors:  Jun Yamamoto; Sachiko Inubushi; Qinghong Han; Yoshihiko Tashiro; Norihiko Sugisawa; Kazuyuki Hamada; Yusuke Aoki; Kentaro Miyake; Ryusei Matsuyama; Michael Bouvet; Steven G Clarke; Itaru Endo; Robert M Hoffman
Journal:  iScience       Date:  2022-03-25

4.  Functional variants of the 5-methyltetrahydrofolate-homocysteine methyltransferase gene significantly increase susceptibility to prostate cancer: Results from an ethnic Han Chinese population.

Authors:  Yuan-Yuan Qu; Shu-Xian Zhou; Xuan Zhang; Rui Zhao; Cheng-Yuan Gu; Kun Chang; Xiao-Qun Yang; Hua-Lei Gan; Bo Dai; Hai-Liang Zhang; Guo-Hai Shi; Yao Zhu; Ding-Wei Ye; Jian-Yuan Zhao
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

5.  Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Shukuan Li; Qinghong Han; Yuying Tan; Kentaro Miyake; Tasuku Kiyuna; Masuyo Miyake; Takashi Murakami; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-12-12

6.  Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.

Authors:  Takashi Murakami; Shukuan Li; Qinghong Han; Yuying Tan; Tasuku Kiyuna; Kentaro Igarashi; Kei Kawaguchi; Ho Kyoung Hwang; Kentaro Miyake; Arun S Singh; Scott D Nelson; Sarah M Dry; Yunfeng Li; Yukihiko Hiroshima; Thinzar M Lwin; Jonathan C DeLong; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-05-30

7.  Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Shukuan Li; Qinghong Han; Yuying Tan; Tasuku Kiyuna; Kentaro Miyake; Takashi Murakami; Bartosz Chmielowski; Scott D Nelson; Tara A Russell; Sarah M Dry; Yunfeng Li; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Oncotarget       Date:  2017-08-12

Review 8.  Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma.

Authors:  Robert M Hoffman
Journal:  Int J Mol Sci       Date:  2017-08-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.